Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowHROW +5.36%80 EV-to-EBITDA is 156.21 as of Aug. 19, 2026, which is 898% above its 10-year median of 15.65. GuruFocus rates HROW with a GF Score™ of 80/100 and a GF Value™ of $42.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 734 Drug Manufacturers companies, Harrow ranks worse than 97.55% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Harrow's enterprise value is $1,777.5 Mil.
Harrow's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $11.4 Mil. Therefore, Harrow's EV-to-EBITDA for today is 156.21.
The historical rank and industry rank for Harrow's EV-to-EBITDA or its related term are showing as below:
HROW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -898.46 Med: 15.65 Max: 2042.5
Current: 156.21
During the past 13 years, the highest EV-to-EBITDA of Harrow was 2042.50. The lowest was -898.46. And the median was 15.65.
HROW's EV-to-EBITDA is ranked worse than 97.55% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs HROW: 156.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-19), Harrow's stock price is $41.63.
Harrow's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.000. Therefore, Harrow's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Harrow's share price for today is $41.63.
Harrow's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Harrow's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Harrow's EV-to-EBITDA falls into.
Harrow's current Enterprise Value is $1,777.5 Mil.
Harrow's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harrow (HROW) has a EV-to-EBITDA of 156.21 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Harrow. This is 898% above median its historical median of 15.65. According to the industry distribution chart, Harrow ranks #716 out of 734 companies in the Drug Manufacturers industry, placing it in the top 97.5%.
Is Harrow's EV-to-EBITDA too high?
Harrow's current EV-to-EBITDA of 156.21 is 898% above median its 10-year median of 15.65. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Harrow's value of 156.21 is 1072.3% above this industry median. Based on the distribution chart, Harrow ranks #716 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Harrow has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's EV-to-EBITDA compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #716 out of 734 companies for EV-to-EBITDA. This places Harrow in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. Harrow's value of 156.21 is 1072.3% above this benchmark. While the company's 10-year median is 15.65 vs. the industry median of 13.33, Harrow has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harrow's current EV-to-EBITDA of 156.21 is 1072.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Harrow. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current EV-to-EBITDA is 156.21, which is 898% above median its own 10-year median of 15.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $42.00, compared to a current price of $41.63 — trading 0.9% below its estimated fair value. The current EV-to-EBITDA is 156.21, which is 898% above median its 10-year median of 15.65 and 1072.3% above the Drug Manufacturers industry median of 13.33. Harrow's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Harrow (HROW), the current EV-to-EBITDA is 156.21 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (HROW) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of $41.63 is trading 0.9% below its estimated GF Value™ of $42.00.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for HROW:
EV-to-EBITDA: 156.21 (898% above median its 10-year median of 15.65)
GF Value™: $42.00 vs. price of $41.63 (0.9% below fair value)
Industry Position: 1072.3% above the Drug Manufacturers median (#716 of 734)
No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
80GF Score
Get the complete analysis for HROW
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HROW has been successfully added to your 
